Global Interferon Gamma Release Assay (IGRA) Market Outlook: Analyzing Drivers from Latent TB Infection Screening and Competitive Strategies, 2025–2032.

 

Overview Of QuantiFERON-TB Gold

The global market for the QuantiFERON-TB Gold (QFT) test—a leading Interferon-Gamma Release Assay (IGRA) used to diagnose Latent Tuberculosis Infection (LTBI)—is experiencing robust growth, driven primarily by the global shift away from the less specific Tuberculin Skin Test (TST). The QFT test, notably the latest version, QuantiFERON-TB Gold Plus (QFT-Plus), offers superior specificity by eliminating false-positive results caused by the BCG vaccine.

This precision makes it a crucial diagnostic tool in high-income and developed regions with stringent screening mandates, such as for healthcare workers and immunocompromised patients.

The increasing global burden of TB and growing awareness campaigns, particularly in developing economies, are further accelerating the adoption of this modern, blood-based diagnostic solution.

Get a Sample Report QuantiFERON-TB Gold Forecast @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-quantiferon-tb-gold-test-market

Market Size, Share, and Forecast

The QuantiFERON-TB Gold Test market was valued at USD 679.48 million in 2024. The market is projected to expand significantly, reaching an estimated value of USD 1,239.15 million by 2032. This growth trajectory corresponds to a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period.

This strong CAGR is indicative of the rapid conversion rate from traditional TST methods to IGRAs and the continued emphasis on early detection and prevention of active tuberculosis, particularly in vulnerable populations.

 The market share is heavily concentrated around the core product, QFT-Plus, which dominates the IGRA segment due to its advanced technology and widespread regulatory approvals.

Segmentation Analysis

The market is segmented based on several key factors:

1.    Brand: Dominated by the QFT-Plus (QuantiFERON-TB Gold Plus) brand, which includes proprietary CD8+ T-cell technology for a more complete immune response assessment.

2.    Test Type (Broader Latent TB Testing Market): While the market is increasingly defined by Interferon Gamma Release Assays (IGRAs), the traditional Tuberculin Skin Test (TST) still holds significant volume, though IGRAs are the faster-growing segment.

3.    Application: Key application areas include screening for People Living with HIV (PLHIV) and high-risk groups such as household contacts of pulmonary TB patients.

4.    End User: The primary end-users are Diagnostic Laboratories, followed by hospitals/clinics and academic & research institutions. Diagnostic labs facilitate the high-throughput, automated testing capabilities required by the QFT platform.

Do you have any specific queries or need any customized QuantiFERON-TB Gold Submit your inquiry here @ https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-quantiferon-tb-gold-test-market

Key Players

The market landscape for the QuantiFERON-TB Gold test is largely consolidated, with the manufacturer of the technology holding a dominant position. Key players in the wider latent TB testing market include:

  • Qiagen (Germany)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Abbott (U.S.)
  • BD (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Hologic, Inc. (U.S.)
  • Meridian Bioscience, Inc. (U.S.)
  • QuidelOrtho Corporation (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)
  • Laboratory Corporation of America Holdings (U.S.)
  • Aster Clinical Lab LLP (India)
  • DiaSorin S.p.A. (Italy)
  • Portea Medical (India)
  • SSI DIAGNOSTICA (Denmark)

This Long-Tail Semantic Indexing (LSI) keyword highlights the core clinical application and purpose of the QuantiFERON-TB Gold test.

Get A Buy Now Report QuantiFERON-TB Gold Forecast @ https://www.databridgemarketresearch.com/checkout/buy/global-quantiferon-tb-gold-test-market/compare-licence

Future Outlook

the QuantiFERON-TB Gold Test market is expected to solidify its position as the preferred method for LTBI diagnosis in developed regions. The high CAGR of 7.8% projected through 2032 is underpinned by continuous technological advancements, such as the QFT-Plus's CD8+ T-cell capability, and the strategic push by leading manufacturers like QIAGEN into emerging, high-burden TB countries.

About Us:

Data Bridge is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

For More Reports:

Passive Electronic Components Market

Subscription Box Market

Load Break Switch Market 

Contact :                                                                                   

Data Bridge Market Research Private Ltd .

3665 Kingsway - Suite 300 Vancouver BC V5R 5W2 Canada

+1 614 591 3140 (US)

 

 

 

 

 

 

 

 

 

Comments

Popular posts from this blog

How will regional markets like Asia Pacific and Japan influence the overall growth trajectory?

Applications of Argan Oil in Food, Pharmaceuticals, and Personal Care

Advances in Biphenyl Derivatives for Electronics and Industrial Manufacturing